Now more than ever, we see the importance of biology: from responding to public health crises to building more resilient supply chains, biology defines what is possible. That’s why we’re so excited to see the Senate take the time to consider biology in the bipartisan Bioeconomy Research and Development Act of 2020, which is set to be marked up by the Senate Commerce Committee on Wednesday, May 20th, 2020. Ginkgo enthusiastically supports this legislation, led by Senator Kirsten Gillibrand (D-NY), Senator Ed Markey (D-MA), Senator Cory Gardner (R-CO) and Senator Marco Rubio (R-FL).
The legislation elevates the importance of a cohesive and coordinated national strategy to guide and expand the field of synthetic biology through the implementation of a National Engineering Biology Research and Development Initiative. This Initiative will facilitate coordination between many U.S. agencies, including DOE, DoD, NIH, NSF, NASA, FDA, USDA, and EPA, to expand synthetic biology research, increase bioeconomy workforce training, and encourage commercialization of biological innovations.
This Initiative will help meet a critical need for federal government action that I recently described in testimony to the Senate Commerce Subcommittee on Science. To ensure America continues to be a leader in synthetic biology, the U.S. government must strategically reinvest in its bioeconomy. The U.S. has done this before with semiconductors, space technology, and ARPANET.
Video from the Securing U.S. Leadership in the Bioeconomy Senate hearing. My testimony begins at 41:27
Synthetic biology will be the world’s next industrial revolution. As proven by the COVID-19 pandemic, our ability to quickly develop new medicines and vaccines using synthetic biology, as well as to manufacture a wide range of essential materials and products in a sustainable and resilient way will define the technology of the 21st century the way that digital technologies defined the 20th. It is essential that the federal government has a cohesive, thoughtful strategy and makes robust investments in research and development programs that underpin the advancement of synthetic biology. The field was born out of U.S. Federal government research investments, and by advancing this legislation, Congress can help ensure American innovators continue to lead in this space.
There is nothing more critical right now than doing what we can to accelerate potential vaccines, diagnostics, and treatments for COVID-19. We’ve rapidly shifted our entire platform towards COVID-19 response, committing $25M of free access to our infrastructure to projects that can support R&D across a range of applications.
I’m thrilled to announce today that as part of that offer, we will be supporting Moderna with process optimization for key raw materials used in the manufacturing of its mRNA vaccines, including mRNA-1273, Moderna’s vaccine candidate against COVID-19, the first to enter clinical trials. With access to our high throughput automated tools for biological engineering, we hope that we can help Moderna accelerate its plans to improve the efficiency of its upstream manufacturing process. You can read more about Moderna’s vaccine efforts here.
We’re eager to support many more efforts in COVID-19, through DNA synthesis, full genome sequencing of SARS-CoV-2 for epidemiological tracking, scaling of diagnostics, antibody lead optimization, and antigen design for serological testing, vaccine, or therapeutic development, among others. If you have a project that you think we can help accelerate with our platform, please reach out to email@example.com.
We’re inspired and heartened by the tremendous public health response to COVID-19, and recognize that a similar scale of effort is needed by the biotech community to find long-term solutions to this crisis. Former FDA commissioner Scott Gottlieb said today:
“We must get a drug and eventually vaccine. We can have treatments, antibody prophylaxis, point of care diagnostics for early detection by fall. That must be [our] focus. #COVID19 doesn’t go away. [The] [i]nitial wave will run course into summer but it’ll be back until our technology stops it.”
We’ve built our platform to enable partners across a wide range of applications to rapidly scale their R&D efforts, and we want to apply this technology today to the fight against the pandemic. To support the people building the treatments that will stop COVID-19 Ginkgo is now offering:
$25M of no-cost foundry work towards projects that can use Ginkgo’s platform to accelerate development of point of care diagnostics, vaccines, or therapeutics. See below for details on how our technologies might be able to support these efforts.
Connection to sources of funding from private and public sources. We are coordinating with people like Sam Altman and others on private funding efforts. If you are interested in funding COVID-19 work, we can connect you to vetted technical teams.
Rapid sharing of R&D information as it is learned among the community of academics and companies working on solutions.
If you are currently a company or academic lab that is developing a diagnostic, drug, or vaccine and are interested in leveraging Ginkgo’s infrastructure at no cost please email us at firstname.lastname@example.org.
Details on Relevant Ginkgo Capabilities:
Ginkgo has invested ~$400M over the last 5 years to build a 100,000 sqft automated facility that is used today to support partners like Roche and Bayer with a broad range of infrastructure for biotechnology R&D. We’ve listed some examples from our discussions with companies developing solutions to COVID-19 below, to help possible partners understand our scope. We will regularly update this list as we find additional areas of leverage we can provide to those working on COVID-19.
For the manufacturing of nucleic acid-based vaccines, we could:
Provide process development capacity with our large bank of ambr250 fermenters for production of vaccine DNA
Assist in developing E. coli or alternative strains for increased production of plasmid or vaccine DNA
Rapidly discover and produce enzymes capable of improving downstream in vitro processing steps specific to the development of mRNA-based vaccines
Use our high-throughput DNA synthesis capacity to rapidly synthesize and screen many designs for vaccine discovery and optimization
To support antibody-based therapeutics development, we could:
Support lead optimization of promising candidate Abs, specifically using rapid DNA synthesis to generate 100s of different Ab designs and inserting these into CHO cells at a precise set of location(s) using cell lines with pre-engineered landing pads
Screening via virus neutralization or (lack of) antibody-dependent enhancement of infectivity leveraging rapid & high throughput screening on the Berkeley Lights Beacon (an optical microfluidics screening platform that we have in-house)
To enable point of care diagnostics, we could:
Rapidly discover enzymes capable of improving CRISPR/Cas-based nucleic acid diagnostics
Use our protein engineering pipeline to further improve key parameters such as diagnostic specificity and selectivity, limit of detection, temperature and storage stability, and overall robustness
Synthesize swap-in/swap-out guide RNA components for CRISPR/Cas-based devices, allowing rapid updating as new viruses need to be detected
Scale protein expression to rapidly optimize production of the enzymes needed for device manufacture
To provide research tools, we could:
Leverage our NGS platform to provide viral sequencing of ~10,000 samples per day. Environmental samples could be sequenced at our facility and we can partner with clinical labs to increase capacity for patient samples.
Synthesize gene length fragments of the SARS-CoV-2 virus in a variety of expression formats and distribute via plasmid repositories to vetted and licensed entities.
More generally, we hope that our capacity for large-scale sequencing, synthesis, analytics, and cell engineering can support and accelerate efforts to develop new diagnostics, biologics, or vaccines for efforts such as those listed above and beyond. We’re looking to commit every part of our platform that can make a difference over the coming months. If you bring us an opportunity that’s not a fit for Ginkgo but can be accomplished by one of our technology partners, we’ll connect you.
We want to help connect great ideas in the community with the resources they need, whether that’s funding or access to technology at Ginkgo or elsewhere, or connections to others working on similar problems. If you have a project that needs support or are looking to contribute resources or expertise to the response and want to be connected to promising efforts, please email us at email@example.com.
At Ginkgo, we believe that the power to program DNA will transform all industries, making technology more adaptive, efficient, and renewable. Engineering living cells has of course already revolutionized the pharma industry, from insulin-producing bacteria in the 1980s all the way to CAR-T cells today.
A few weeks ago we announced our acquisition of the Warp Drive genome mining platform and a partnership with Roche, using synthetic biology to discover novel small molecule medicines made by bacteria. Today I’m thrilled to announce an expansion of our partnership with Synlogic, who is ushering in a new paradigm for therapeutics, where the bacteria aren’t just making the medicine, they are the medicine.
Synlogic is developing an incredible platform that enables them to program probiotic bacteria to treat many different complex diseases using the power of biology. Living cells have the ability to do what chemicals can’t: they can sense and respond, they can deliver enzymes and small molecules directly where they’re needed, and they can consume and break down potentially toxic molecules before they cause any harmful effects. Today, Synlogic’s pipeline includes strains of E. coli that live in the gut and consume molecules like phenylalanine or ammonia in diseases where patients’ bodies are unable to do this on their own, leading to toxicity and neurological damage if left untreated. They also are working on engineered bacteria that can be injected directly into tumors, sending up signal flares that alert the immune system to attack the cancer cells.
As organism designers, we’re so excited by Synlogic’s vision and we’ve been so inspired by the talent and passion of the team and their ability to program cells to fight so many different diseases. Their expertise is a perfect complement to the work we do programming cells in our foundries and we’ve been collaborating successfully with Synlogic since late 2017. We’ve been thrilled by the promising early results for our first collaborative project that shows how our two companies can work together to accelerate the development of a new living medicine.
Synlogic had developed an early prototype strain for the treatment of a rare metabolic disease that was promising but had room for improvement. In our foundry, we prototyped and screened over 1000 versions of each of the three enzymes in the designed pathway, zeroing in on the sequences with the highest activity in combination. Because of the scale of our foundries to build and test so many strains, we could help Synlogic’s scientists choose the best strains with significantly improved function both in vitro and in vivo. We’ll be sharing all those details and the results from nonhuman primate studies at the SEED conference in a couple weeks.
Based off of the success of our proof of concept partnership and the enormous potential that Synlogic has in therapeutics, today we are excited to announce an expansion of our collaboration to drive new innovation in living medicines through the combined strength of Synlogic’s expertise in drug design and development and Ginkgo’s foundries for biological engineering. We are making a premium equity investment of $80M and beginning a range of new projects, expanding Synlogic’s pipeline and helping accelerate more promising candidates to the clinic.
We see living medicines as the source of many future drugs. Recombinant DNA technology first made it possible to manufacture protein-based drugs nearly forty years ago, and today a large percentage of promising new drugs are biologics. We can only imagine what might be possible in the age of living programmable medicines.
When people talk about the future of food, they often start by talking about how the human population is projected to reach 10 billion people by the year 2050. To feed a rapidly growing population with an expanding middle class on a warming planet, we’ll have to use new technologies and build new systems to grow and distribute food. But whether it’s about choosing our next meal or feeding a growing population, the stories we tell about the future of food are full of impossible tradeoffs between taste, cost, health, and the environment (think Soylent vs. Whole Foods). And when it comes to GMOs specifically, the tradeoff is even more stark. Will it ever be possible for food be sustainable, healthy, delicious, and affordable?
At Ginkgo, we believe that biotechnology is an essential part of the future of food, and we hope that it can give us more options, not fewer. We’re working towards a future where genetic engineering and cultured ingredients can help make foods that are more sustainable, healthier, delicious, and more accessible for everyone. It’s what drives our work with customers in the flavor & fragrance and food industries to make cultured ingredients and the work of Joyn Bio, our joint venture with Bayer engineering microbes for more sustainable agriculture.
Today we’re thrilled to be launching Motif Ingredients, a new company built on Ginkgo’s platform to address one of the biggest challenges and changes emerging for the future of food—protein. Recognizing the benefits to health and sustainability that come from a plant-based diet, consumer demand for complements to animal proteins has exploded in the past few years, for products ranging from oat milk to “bleeding” veggie burgers. Companies ranging from brand new startups to industry giants have rapidly innovated new foods based on alternative proteins, but there’s so much more to do to make these options as healthy, delicious, sustainable, and accessible as they should be. Motif Ingredients will use Ginkgo’s Foundry to discover and develop these necessary new alternative protein ingredients that can be made via fermentation, not animal agriculture.
Motif Ingredients is launching today with $90M in Series A funding from Breakthrough Energy Ventures, Fonterra, Louis Dreyfus Company, and Viking Global Investors. Our investors come from both high tech venture capital and traditional food producers that have been feeding the world for more than a century, all believing in our platform’s ability to deliver more alternatives for everyone’s “food future”. Motif will operate from Ginkgo’s offices in the Boston Seaport and leverage our foundries to discover the next generation of alternative proteins. We’re also excited to welcome industry veteran Jon McIntyre to the team as Motif’s CEO. Formerly the head of R&D at Indigo Ag and prior to that, a Senior VP of R&D at PepsiCo, Jon brings a wealth of experience in global food systems and alternative proteins to Motif.
A platform for discovering the next generation of food proteins
Proteins in animal products like meat, dairy, and eggs are essential for the taste, texture, nutrition, health impact, and overall experience of many foods that we eat. Food proteins have unique structural and functional properties, whether they are egg proteins giving a dessert its fluffy texture, or milk proteins protecting a baby’s digestive system from dangerous bacteria. Motif will make different proteins like these via fermentation of engineered microbes, without animal agriculture, to create a rich palette of alternative protein ingredient options for people developing new foods.
Ginkgo’s platform enables biological engineers to deeply study thousands of different protein options across a vast space of biological diversity, discover the proteins that provide the greatest functional benefit, and increase their accessibility at large scale. There is so much that we don’t yet know about even the most common foods, so the ability to search this breadth of biological diversity is essential. Even in the last 5 years, hundreds of new proteins have been discovered in milk and eggs that confer benefits to people who eat them. With Motif, we’re on a mission to explore all that animal proteins have to offer, to enable the next generation of alternative proteins.
Beyond cow’s milk and hen’s eggs, there are also foods with vital benefits that are impossible to access in large amount sustainably, such as sturgeon eggs, camel milk, and everything in between. Just one year ago, scientists discovered a new protein in platypus milk that has surprising antibiotic properties. Using DNA sequence analysis and synthesis, Motif’s scientists will be able to discover and produce hundreds of proteins from many different animals, to understand how their milk and eggs nourish and sustain life in its earliest stages and identify important new ingredients.
At Ginkgo, we are always learning from the creativity of biology and the full breadth of biodiversity to grow better, more sustainable products. We’re so excited to work with Motif as they look to biodiversity to find the proteins that will enable new creativity in food. We’re thrilled to welcome Motif to our platform and to support the next generation of chefs, food designers, and food visionaries who need new ingredients and tools for the future of food.
Cannabis is a fascinating and rapidly growing industry, predicted to reach $57 billion worldwide by 2027. As legalization spreads, so too does our understanding of the potential benefits of the many different molecules present in the plant.
Beyond the better known THC and CBD, cannabinoids present in tiny quantities in the plant have the potential to be valuable in a range of pharmaceutical applications. Ongoing research has shown potential medicinal uses for indications such as chronic pain, nervous disorders, nausea, weight loss, and some mental illnesses.
But to unlock the value of these molecules, we first need to be able to access them. Today we’re announcing a partnership with Toronto-based Cronos Group to produce a range of different cannabinoid molecules through fermentation of engineered yeasts. It’s a large-scale and long-term deal, involving up to $22M for R&D along with a total of up to $100 million worth of Cronos common shares upon achieving pilot commercial scale.
There are hundreds of different cannabinoids produced by different varietals of the plant. Long term breeding has led to strains that produce large amounts of THC(A) and CBD(A) (the A stands for acid, a different chemical form that is converted to THC and CBD when heated) but other molecules such as CBC, CBG, and THCV are present only in trace amounts, meaning that they are impractical or impossible to extract and purify from the plant. Without a cost effective supply, research into the pharmaceutical properties of these molecules has also been hampered. THCV, for example, has been shown at low doses to offer relief from anxiety without the appetite stimulating effects of THC, but so much is still unknown.
By transferring the DNA sequences for cannabinoid production into yeast, using the foundry and our existing high-throughput fermentation processes, we’ll work to construct strains that produce a range of different cannabinoids at high quality and purity, identical to those extracted from the plant with traditional methods. By capitalizing on the power of biological manufacturing, we can unlock access to medically important cannabinoids that can be scaled up and produced reliably.
We’re so excited to be working with the Cronos Group on this landmark partnership. Cronos, based in Canada and with a presence across four continents, is a vertically integrated cannabis company that operates two licensed producers regulated under Health Canada’s Access to Cannabis for Medical Purposes Regulations. Cronos, with access to an array of varietals and a deep expertise in plant genetics, has gathered extensive data on cannabinoids and their properties. This allows them to generate the best recipes for the full spectrum of cannabinoids, not just the most common ones.
We’ll be working to develop strains of yeast that can produce eight different cannabinoids. All the R&D work we’ll be doing at Ginkgo will of course be conducted in compliance with all U.S. federal laws regarding controlled substances, and we’re currently waiting for approval from from Federal and State agencies. Cronos Group intends to produce and distribute the cultured cannabinoids that result from our partnership globally, and has received confirmation that this method of production is permitted under the Cannabis Act—the legal framework that will regulate cannabis in Canada.
As Ginkgo has grown, we’ve seen the power of biological engineering and fermentation to unlock the potential of a huge variety of molecules in several industries, from flavor and fragrance to pharmaceuticals. We’re thrilled to be working with Cronos as they build the world’s most innovative cannabinoid platform to bring these products to life.
Our mission is to make biology easier to engineer—that hasn’t changed for the ten years we’ve been building Ginkgo. The ability to read, write, and design DNA code is having profound positive impacts in medicine, agriculture, and manufacturing, from engineered cell therapies that can target a person’s cancer cells, to probiotics for plants that can reduce the need for nitrogen fertilizers, to sustainably grown materials.
We are working to unlock the enormous power of biology: its ability to grow sustainably, to process information, and adapt to changing environments. But we’re not naive to the potential risks. We understand that as it becomes easier to engineer biology, it will become easier to engineer the part of biology that’s dangerous to humans, animals, and plants—the pathogens and parasites that can infect us. Since researchers synthesized the polio virus in 2002, it has been technically possible to chemically synthesize viruses that infect humans
To date, the work done on synthesizing viruses has been intended for medical research and other peaceful purposes, but there is a concern that someone could theoretically produce a virus or other pathogen with the intent to harm. The intentional use of pathogens to harm others is abhorrent and something that I believe that we should never do under any circumstances—as a company and as human beings. The international community agrees with me on this: 180 countries including the United States are parties to the UN Biological Weapons Convention, which was first signed in 1972 and states that we are “never in any circumstance to develop, produce, stockpile, or otherwise acquire or retain: Microbial or other biological agents, or toxins…that have no justification for prophylactic, protective or other peaceful purposes.”
Today we’re announcing Ginkgo’s biosecurity initiative that directly addresses some of these potential threats from engineered DNA sequences. Our current work on biosecurity focuses primarily on detecting potential threats using software that analyzes DNA sequences.
As part of IARPA’s (the Intelligence Advanced Research Projects Activity) Fun GCAT program, we are developing software to monitor DNA synthesis. This software is intended to ensure that no one orders DNA sequences that could have a pathogenic function. Think of this like a malware detector in computer programming—“programs” being written in synthetic DNA will go through the detector software, which will flag any sequences of concern before they are synthesized. The custom software we’ve developed for designing DNA sequences in our foundries is a useful start for a project like this—we need to be able to predict the function of enzymes based on their sequences in order to design new functions in our engineered microbes. Rather than predicting if an enzyme sequence could be used to produce, say, a fragrance or vitamin, here we’re applying the same types of algorithms to predict whether a given bit of code could be potentially harmful.
Unlike computer viruses, however, new biological viruses can also evolve in the wild. When a new virus emerges, researchers quickly sequence it to understand where it came from and how to best treat it and develop vaccines against it. We’re addressing this as part of another software-based biosecurity initiative, IARPA’s Finding Engineered Linked Indicators (FELIX) program. Here we are using deep learning to identify if the sequence of a new pathogen developed naturally or was engineered by humans. We’re leveraging our experience engineering the world’s largest library of engineered DNA sequences to help us train the software to detect whether something has been engineered.
Beyond developing software to guide the detection of threats, synthetic biology can also be important for responding to emerging diseases, for example making rapid response vaccines. It’s been almost a decade since the Venter institute partnered with Novartis on rapid synthetic DNA based vaccine development and the technology has been exponentially improving since then. Working alongside other companies, universities, and government agencies, we’re excited to be part of groups involved in developing tools to prevent, diagnose, and treat current and emerging diseases.
Ginkgo is the leading developer of genetic engineering tools we have an obligation to ensure that these tools are responsibly used. We are inspired by the words of Andy Weber, the former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs under President Obama and a valued advisor to us here at Ginkgo on issues of biosecurity: we believe that while synthetic biology may lead to new risks, that these new tools also actually “offer the opportunity to take the global threat of biological weapons off the table.” By helping to develop software that can detect any threats before they materialize and develop the tools that can rapidly respond to emerging infectious diseases—natural or engineered—we hope to continue to drive the responsible growth of synthetic biology and realize its enormous potential for good.
I’m happy to share we’ve been named to the CNBC Disruptor 50 list for the third year in a row. During these three years, Ginkgo has grown a lot, into new foundries and new industries. We’re now a team of almost 200 people and 65 robots and counting, still dreaming about how biology will change how we make things.
Today, it’s a given that Silicon Valley and software are disrupting traditional ways of doing business, across media, financial services, logistics, transportation, healthcare, and many other things that once seemed to be far removed from computers and information technology. In 2011, Marc Andreessen aptly proclaimed that “software is eating the world”— in other words, that more sectors would be disrupted by and start to look like software companies.
A biotechnology company among a list of such disruptive companies could perhaps look like a software company, signaling just another sector eaten by software. But I think that would miss the point of innovating with biology.
In short, you can’t eat software.
Bits aren’t calories. A mobile app might help me decide what to eat for dinner and software will handle the logistics of how it gets to my door, but software doesn’t fill my stomach. I can’t taste software or smell it. I need more than just software to keep the lights on; I can’t wear it to keep warm. Software will help us discover important patterns in healthcare and medicine, but I can’t take a software pill to get well. Software can have many positive effects, but as Bill Gates has said about technology needs in the developing world: “When a kid gets diarrhea, no, there’s no website that relieves that.”
Designing DNA makes it possible to fundamentally disrupt the many unsustainable ways we make things today, to improve how we produce food, design medicines, and manufacture materials and chemicals. Learning from the wisdom of three billion years of biological evolution, we can tap into the ways living things grow, heal, and adapt in deeply circular and interconnected ways to make technology that is rooted in nature. From meat to medicines, vitamins, flavors, and everyday household products, biology companies are rethinking our manufacturing system and transforming cells into living factories to grow the products that will help meet growing global demand.
Even two industries that are fundamentally about biology—pharma and agriculture—are being biologically transformed by new ways of engineering cells. In 2016, 25% of pharma sales were from biologics like proteins and antibodies that are produced through genetic engineering. Today, we are seeing the beginning of a new generation of living therapeutics and engineered cell therapies, like those we are developing with Synlogic. In ag, new innovation is targeting the chemical inputs necessary for large-scale farming, replacing them with more sustainable biologic products. Just last year we founded Joyn Bio, our joint venture with Bayer to develop probiotics that could decrease the amount of chemical fertilizer – a major contributor to greenhouse gas emissions – needed in agriculture.
But because we are biology, the stakes for disruption are also much higher for biotechnology. The power of biology is what inspires us and drives us to build this industry, but it’s also something we have great respect for and must approach with humility. Evolution has 3 billion years on us, and we don’t take that lightly.
With respect for biology at its core, the disruption that biotechnology offers is one that is going to enable more sustainable manufacturing, less fossil fuel intensive agriculture, smarter medicines, and so much more. We’re so excited to be part of that.
SynBioBeta San Francisco 2017: Why the Future of Synthetic Biology Needs a Platform
Today, the Ginkgo team and I are attending the 6th annual SynBioBeta conference in San Francisco—an annual meeting that brings together leaders in the synthetic biology industry. I’m kicking off the day discussing why biology is the most powerful and advanced technology on the planet and Ginkgo’s mission is to make biology easier to engineer.
We’re witnessing an exciting shift in the biotech world. Companies big and small across a variety of industries—from enzymes to fragrances to agriculture—are realizing the power of biology as a better way to make everyday ingredients and products.
Last month, we partnered with Bayer to launch a new company—along with a $100M Series A investment—to improve plant-associated microbes, focusing on nitrogen fixation. Nitrogen fertilizer is a significant contributor to greenhouse gas emissions and water pollution, and we’re proud to be at the forefront of solving such a major problem with biology.
We hope this partnership serves as a major indicator for synthetic biology’s potential: big companies are looking to solve big problems with this technology. But more importantly, we believe the potential for biology doesn’t have to come with a $100M investment. Smaller companies are also rethinking manufacturing through biology, and we’re committed to being a platform that’s accessible to companies of all industries and all budgets.
Today we have three announcements that help cement our vision for being a universal and accessible platform for the biotech world:
• We’ve long-admired Transcriptic’s mission to make lab work less expensive and faster thanks to the power of automation. Today we’re investing over $10 million to bring their software into our foundries, to further improve our automation processes.
• We’re teaming up with Geltor, an 8-person company creating texturizing proteins for foods and cosmetic products, to help it make products faster and more efficiently. With our foundry, Geltor’s team can focus on product design and development, and more importantly make biotech timelines compatible with business cycles in the CPG markets.
• To support our growth, we’ll be purchasing one billion pairs of synthetic DNA from our longtime partner Twist Bioscience. It’s a historic purchase, and ensures we’re ready to support the needs of today’s customers and tomorrow’s partners.
I’m incredibly proud of what our team has built so far. We’ve designed a platform that powers big and small customers, while allowing partners to build on top of our technology to create something even greater. At the same time, I’m humbled by what lies ahead. We’re looking forward to meeting other consumer biotech companies this week at SynBioBeta to learn about their roadblocks and hope that Ginkgo can play a role in contributing to their success!
2017 So Far: Growing our Technology & Our Team Jason Kelly, Ginkgo Bioworks co-founder and CEO
The first half of 2017 has been nothing short of incredible for Ginkgo. We acquired Gen9 in January to bring their DNA synthesis capabilities in-house, and last month announced successful commercial-scale fermentation of an ingredient with our partner Robertet. Both of these were significant milestones in our work on continuing to scale our technology, but we know there’s more work to do.
Today, we’re officially announcing two new additions to our team here at Ginkgo who will play a huge role in our ability to continue to scale: Ena Cratsenburg, our chief business officer, and Will Schroeder, head of metabolic engineering. Ena has over a decade of business development experience in biotech, but also spent more than five years with Pixar. She’s already brought that mix of practical experience and outside-the-box thinking to her role overseeing new partnerships and the commercialization of our tech and products. You can read more about Ena’s day-to-day experience at Ginkgo here, and how she found her way from Pixar to biotech.
Will serves as our new head of metabolic engineering, managing the teams of organism engineers designing the microbes that produce cultured ingredients for our customers. He comes to us from ADM and spent 12 years at Cargill. Both of these companies are partners of ours, and it’s great to have Will’s unique understanding of the industry and incredible expertise in enzymes (he’s the author or inventor of 16 publications and patents in the areas of microbial fermentation, molecular biology and enzyme catalysis!).
Please join me in welcoming Will and Ena to the team! You can read more about our commitment to diversity in our hiring practices here, and see open job recs here.